Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL).

Trial Profile

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL).

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Rosiglitazone (Primary) ; Fenofibrate
  • Indications Hypercholesterolaemia; Hypertriglyceridaemia
  • Focus Pharmacodynamics
  • Acronyms RAFAEL
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Feb 2014 Status changed from completed to discontinued as reported by record.
    • 07 Jul 2010 Actual end date (May 2010) added as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top